Compendium of Cancer Genome Aberrations

Changes

Volunteer Assignments and Opportunities (view source)

Revision as of 16:39, 3 February 2023

820 bytes added ,  16:39, 3 February 2023
no edit summary
Line 754: Line 754:  
|
 
|
 
|
 
|
−
| ||Yassmine Akkari (YA)
+
| ||Holly Drendel (HD)
−
|
   
|
 
|
 +
|YA (prior AE)
 
|-
 
|-
 
|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''||
 
|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''||
Line 762: Line 762:  
|
 
|
 
|
 
|
−
| ||YA
+
| ||HD
−
|
   
|
 
|
 +
|YA (prior AE)
 
|-
 
|-
 
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain (trainee) + Yassmine Akkari
 
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain (trainee) + Yassmine Akkari
Line 770: Line 770:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||YA
+
| ||HD
−
|
   
|
 
|
 +
|YA (prior AE)
 
|-
 
|-
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(v;11q23.3); KMT2A-Rearranged||Disease||Yassmine Akkari+Nicolas Millan (trainee)
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(v;11q23.3); KMT2A-Rearranged||Disease||Yassmine Akkari+Nicolas Millan (trainee)
Line 779: Line 779:  
|PENDING
 
|PENDING
 
|
 
|
−
|YA
+
|HD
−
|
   
|
 
|
 +
|YA (prior AE)
 
|-
 
|-
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||Marilena Melas + Yassmine Akkari
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||Marilena Melas + Yassmine Akkari
Line 787: Line 787:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||YA
+
| ||HD
−
|
   
|
 
|
 +
|YA (prior AE)
 
|-
 
|-
 
|    B-Lymphoblastic Leukemia/Lymphoma with  Hyperdiploidy||Disease||Afia Hasnain + Yassmine Akkari
 
|    B-Lymphoblastic Leukemia/Lymphoma with  Hyperdiploidy||Disease||Afia Hasnain + Yassmine Akkari
Line 795: Line 795:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||YA
+
| ||HD
−
|
   
|
 
|
 +
|YA (prior AE)
 
|-
 
|-
 
|    B-Lymphoblastic Leukemia/Lymphoma with  Hypodiploidy||Disease||Ashwini Yenamandra +
 
|    B-Lymphoblastic Leukemia/Lymphoma with  Hypodiploidy||Disease||Ashwini Yenamandra +
Line 806: Line 806:  
|Complete
 
|Complete
 
|
 
|
−
|YA
+
|HD
−
|
   
|
 
|
 +
|YA (prior AE)
 
|-
 
|-
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(5;14)(q31.1;q32.1); IGH/IL3||Disease||Binu Porath + Linda Cooley
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(5;14)(q31.1;q32.1); IGH/IL3||Disease||Binu Porath + Linda Cooley
Line 814: Line 814:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||YA
+
| ||HD
−
|
   
|
 
|
 +
|YA (prior AE)
 
|-
 
|-
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(1;19)(q23;p13.3); TCF3-PBX1||Disease||Binu Porath + Linda Cooley
 
|    B-Lymphoblastic Leukemia/Lymphoma with  t(1;19)(q23;p13.3); TCF3-PBX1||Disease||Binu Porath + Linda Cooley
Line 822: Line 822:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||YA
+
| ||HD
−
|
   
|
 
|
 +
|YA (prior AE)
 
|-
 
|-
 
|    B-Lymphoblastic Leukemia/Lymphoma,  BCR-ABL1-Like||Disease||Mark G. Evans + Fabiola Quintero-Rivera
 
|    B-Lymphoblastic Leukemia/Lymphoma,  BCR-ABL1-Like||Disease||Mark G. Evans + Fabiola Quintero-Rivera
Line 831: Line 831:  
|Complete
 
|Complete
 
|
 
|
−
|YA
+
|HD
−
|
   
|
 
|
 +
|YA (prior AE)
 
|-
 
|-
 
|    B-Lymphoblastic Leukemia/Lymphoma with  iAMP21||Disease||Holli Drendel
 
|    B-Lymphoblastic Leukemia/Lymphoma with  iAMP21||Disease||Holli Drendel
Line 839: Line 839:  
|
 
|
 
|Complete
 
|Complete
−
| ||YA
+
| ||HD
−
|
   
|
 
|
 +
|YA (prior AE)
 
|-
 
|-
 
|    B-Lymphoblastic Leukemia/Lymphoma, Not  Otherwise Specified||Disease||Holli Drendel
 
|    B-Lymphoblastic Leukemia/Lymphoma, Not  Otherwise Specified||Disease||Holli Drendel
Line 847: Line 847:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||YA
+
| ||HD
−
|
   
|
 
|
 +
|YA (prior AE)
 
|-
 
|-
 
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
 
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
Line 858: Line 858:  
|PENDING
 
|PENDING
 
|
 
|
−
|YA
+
|HD
 
|
 
|
−
|NON-WHO ENTITY
+
|YA (prior AE); NON-WHO ENTITY
 
|-
 
|-
 
|B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
 
|B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
Line 869: Line 869:  
|PENDING
 
|PENDING
 
|
 
|
−
|YA
+
|HD
 
|
 
|
−
|NON-WHO ENTITY
+
|YA (prior AE); NON-WHO ENTITY
 
|-
 
|-
 
|B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
 
|B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
Line 880: Line 880:  
|PENDING
 
|PENDING
 
|
 
|
−
|YA
+
|HD
 
|
 
|
−
|NON-WHO ENTITY
+
|YA (prior AE); NON-WHO ENTITY
 
|-
 
|-
 
|B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
 
|B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
Line 891: Line 891:  
|PENDING
 
|PENDING
 
|
 
|
−
|YA
+
|HD
 
|
 
|
−
|NON-WHO ENTITY
+
|YA (prior AE); NON-WHO ENTITY
 
|-
 
|-
 
|B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
 
|B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
Line 902: Line 902:  
|PENDING
 
|PENDING
 
|
 
|
−
|YA
+
|HD
 
|
 
|
−
|NON-WHO ENTITY
+
|YA (prior AE); NON-WHO ENTITY
 
|-
 
|-
 
|B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
 
|B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
Line 913: Line 913:  
|PENDING
 
|PENDING
 
|
 
|
−
|YA
+
|HD
 
|
 
|
−
|NON-WHO ENTITY
+
|YA (prior AE); NON-WHO ENTITY
 
|-
 
|-
 
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||Fei Yang
 
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||Fei Yang
Line 921: Line 921:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||YA
+
| ||HD
−
|
   
|
 
|
 +
|YA (prior AE)
 
|-
 
|-
 
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||Fei Yang
 
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||Fei Yang
Line 929: Line 929:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||YA
+
| ||HD
 
|
 
|
−
|2021 template added
+
|YA (prior AE); 2021 template added
 
|-
 
|-
 
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang
 
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang
Line 937: Line 937:  
|
 
|
 
|PENDING
 
|PENDING
−
| ||YA
+
| ||HD
 
|
 
|
−
|2021 template added
+
|YA (prior AE); 2021 template added
 
|-
 
|-
 
| || ||
 
| || ||
Line 953: Line 953:  
|
 
|
 
|
 
|
−
| ||Snehal Patel (SP)
+
| ||Shivani Golem (SG)
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||
 
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||
Line 962: Line 962:  
|
 
|
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|       Monoclonal B-cell  Lymphocytosis||Disease||Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
 
|       Monoclonal B-cell  Lymphocytosis||Disease||Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
Line 971: Line 971:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SG
 
|
 
|
−
|2021 template added
+
|SP (prior AE), 2021 template added
 
|-
 
|-
 
|B-cell Prolymphocytic Leukemia||Disease||
 
|B-cell Prolymphocytic Leukemia||Disease||
Line 980: Line 980:  
|
 
|
 
|
 
|
−
|SP
+
|SG
 
|
 
|
−
|2021 template added; No longer an entity
+
|SP (prior AE); 2021 template added; No longer an entity
 
|-
 
|-
 
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
 
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
Line 989: Line 989:  
|Complete
 
|Complete
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Hairy Cell Leukemia||Disease||Snehal Patel
 
|Hairy Cell Leukemia||Disease||Snehal Patel
Line 998: Line 998:  
|Complete
 
|Complete
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel
 
|'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel
Line 1,007: Line 1,007:  
|Complete
 
|Complete
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Splenic Diffuse Red  Pulp Small B-cell Lymphoma||Disease||Snehal Patel
 
|    Splenic Diffuse Red  Pulp Small B-cell Lymphoma||Disease||Snehal Patel
Line 1,016: Line 1,016:  
|Complete
 
|Complete
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Hairy Cell Leukemia  Variant||Disease||Snehal Patel
 
|    Hairy Cell Leukemia  Variant||Disease||Snehal Patel
Line 1,025: Line 1,025:  
|Complete
 
|Complete
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Lymphoplasmacytic Lymphoma||Disease||Kapitolina Semenova (trainee)+Fabiola Quintero-Rivera
 
|Lymphoplasmacytic Lymphoma||Disease||Kapitolina Semenova (trainee)+Fabiola Quintero-Rivera
Line 1,034: Line 1,034:  
|PENDING review  by FQR
 
|PENDING review  by FQR
 
|
 
|
−
|SP
+
|SG
 
|
 
|
−
|2021 template added
+
|SP (prior AE); 2021 template added
 
|-
 
|-
 
|   Waldenstrom  Macroglobulinemia||Disease||Kapitolina Semenova (trainee)+Fabiola Quintero-Rivera
 
|   Waldenstrom  Macroglobulinemia||Disease||Kapitolina Semenova (trainee)+Fabiola Quintero-Rivera
Line 1,043: Line 1,043:  
|PENDING review  by FQR
 
|PENDING review  by FQR
 
|
 
|
−
|SP
+
|SG
 
|
 
|
−
|2021 template added
+
|SP (prior AE); 2021 template added
 
|-
 
|-
 
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
 
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
Line 1,051: Line 1,051:  
|
 
|
 
|
 
|
−
| ||SP
+
| ||SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|'''''Heavy Chain Diseases'''''||'''''Overview'''''||
 
|'''''Heavy Chain Diseases'''''||'''''Overview'''''||
Line 1,059: Line 1,059:  
|
 
|
 
|
 
|
−
| ||SP
+
| ||SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Mu Heavy Chain  Disease||Disease||
 
|    Mu Heavy Chain  Disease||Disease||
Line 1,067: Line 1,067:  
|
 
|
 
|
 
|
−
| ||SP
+
| ||SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|   Gamma Heavy Chain  Disease||Disease||Manisha Sutariya
 
|   Gamma Heavy Chain  Disease||Disease||Manisha Sutariya
Line 1,075: Line 1,075:  
|
 
|
 
|Complete
 
|Complete
−
|5/26/2021||SP
+
|5/26/2021||SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Alpha Heavy Chain  Disease||Disease||
 
|    Alpha Heavy Chain  Disease||Disease||
Line 1,083: Line 1,083:  
|
 
|
 
|
 
|
−
| ||SP
+
| ||SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang
 
|Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang
Line 1,092: Line 1,092:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|   Non-IgM Monoclonal  Gammopathy of Undetermined Significance||Disease||Zhenya Tang
 
|   Non-IgM Monoclonal  Gammopathy of Undetermined Significance||Disease||Zhenya Tang
Line 1,101: Line 1,101:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee)
 
|    Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee)
Line 1,110: Line 1,110:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Plasma Cell Myeloma Variants||Disease||Fariborz Rashid-Kolvear
 
|    Plasma Cell Myeloma Variants||Disease||Fariborz Rashid-Kolvear
Line 1,119: Line 1,119:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Plasmacytoma||Disease||Zhenya Tang
 
|    Plasmacytoma||Disease||Zhenya Tang
Line 1,128: Line 1,128:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||Chen Yang, MD, PhD
 
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||Chen Yang, MD, PhD
Line 1,136: Line 1,136:  
|
 
|
 
|Complete
 
|Complete
−
|09/10/2022||SP
+
|09/10/2022||SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|           Primary  Amyloidosis||Disease||Heather E. Williams, PhD
 
|           Primary  Amyloidosis||Disease||Heather E. Williams, PhD
Line 1,144: Line 1,144:  
|
 
|
 
|?PENDING
 
|?PENDING
−
| ||SP
+
| ||SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|           Light Chain and Heavy Chain Deposition Disease||Disease||Chen Yang, MD, PhD
 
|           Light Chain and Heavy Chain Deposition Disease||Disease||Chen Yang, MD, PhD
Line 1,152: Line 1,152:  
|
 
|
 
|Complete
 
|Complete
−
|10/15/2022||SP
+
|10/15/2022||SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||Sohini Anand
 
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||Sohini Anand
Line 1,160: Line 1,160:  
|9/15/2021
 
|9/15/2021
 
|PENDING
 
|PENDING
−
| ||SP
+
| ||SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|         POEMS Syndrome||Disease||Sohini Anand, MBBS, and Tharanga Niroshini Senaratne, PhD
 
|         POEMS Syndrome||Disease||Sohini Anand, MBBS, and Tharanga Niroshini Senaratne, PhD
Line 1,168: Line 1,168:  
|
 
|
 
|?PENDING
 
|?PENDING
−
| ||SP
+
| ||SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|         TEMPI Syndrome||Disease||Sohini Anand, MBBS
 
|         TEMPI Syndrome||Disease||Sohini Anand, MBBS
Line 1,176: Line 1,176:  
|
 
|
 
|?PENDING
 
|?PENDING
−
| ||SP
+
| ||SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee (trainee)/Fabiola Quintero-Rivera
 
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee (trainee)/Fabiola Quintero-Rivera
Line 1,185: Line 1,185:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SG
 
|
 
|
−
|2021 template added
+
|SP (prior AE); 2021 template added
 
|-
 
|-
 
|Nodal Marginal Zone Lymphoma||Disease||Shivani Golem
 
|Nodal Marginal Zone Lymphoma||Disease||Shivani Golem
Line 1,193: Line 1,193:  
|
 
|
 
|Complete
 
|Complete
−
|5/28/2021||SP
+
|5/28/2021||SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Paediatric Nodal Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
 
|    Paediatric Nodal Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
Line 1,202: Line 1,202:  
|Complete
 
|Complete
 
|11/11/2020
 
|11/11/2020
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Follicular Lymphoma||Disease||Ruthann Pfau
 
|Follicular Lymphoma||Disease||Ruthann Pfau
Line 1,211: Line 1,211:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Testicular Follicular Lymphoma||Disease||Ruthann Pfau
 
|    Testicular Follicular Lymphoma||Disease||Ruthann Pfau
Line 1,220: Line 1,220:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    In Situ Follicular Neoplasia||Disease||Ruthann Pfau
 
|    In Situ Follicular Neoplasia||Disease||Ruthann Pfau
Line 1,229: Line 1,229:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Duodenal-Type Follicular Lymphoma||Disease||Ruthann Pfau
 
|    Duodenal-Type Follicular Lymphoma||Disease||Ruthann Pfau
Line 1,238: Line 1,238:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
 
|Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
Line 1,247: Line 1,247:  
|Complete
 
|Complete
 
|8/16/2020
 
|8/16/2020
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||Afia Hasnaid
 
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||Afia Hasnaid
Line 1,255: Line 1,255:  
|9/30/20
 
|9/30/20
 
|Complete
 
|Complete
−
|5/26/2021||SP
+
|5/26/2021||SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Primary Cutaneous Follicle Centre Lymphoma||Disease||Shivani Golem
 
|Primary Cutaneous Follicle Centre Lymphoma||Disease||Shivani Golem
Line 1,264: Line 1,264:  
|Complete
 
|Complete
 
|09/10/2022
 
|09/10/2022
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|Mantle Cell Lymphoma||Disease||Mahsa Khanlari
 
|Mantle Cell Lymphoma||Disease||Mahsa Khanlari
Line 1,273: Line 1,273:  
|PENDING
 
|PENDING
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||Tsigab Hagos (trainee)/Shashirekha.Shetty
 
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||Tsigab Hagos (trainee)/Shashirekha.Shetty
Line 1,282: Line 1,282:  
|Pending
 
|Pending
 
|
 
|
−
|SP
+
|SG
−
|
   
|
 
|
 +
|SP (prior AE)
 
|-
 
|-
 
|    In Situ Mantle Cell  Neoplasia||Disease||Rina Kansal, MD
 
|    In Situ Mantle Cell  Neoplasia||Disease||Rina Kansal, MD
Line 1,291: Line 1,291:  
|Complete
 
|Complete
 
|7/26/2022
 
|7/26/2022
−
|SP
+
|SG
 
|
 
|
−
|2021 template added
+
|SP (prior AE); 2021 template added
 
|-
 
|-
 
| || ||
 
| || ||
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/11757"